Robert Schnepp

Robert Schnepp is a Senior Director in the Oncology Asset Development Team at Merck, where they collaborate on developing patritumab deruxtecan to enhance therapies for patients with aggressive cancers. Previously, they served as Senior Medical Director at Johnson & Johnson, leading innovative studies on amivantamab in various malignancies and directing strategic efforts in clinical development. They also worked at Children’s Healthcare of Atlanta and the Children’s Hospital of Philadelphia as an attending physician, and held an assistant professor position at Emory University, where their research focused on aggressive pediatric solid tumors. Robert earned an MD/PhD from the Perelman School of Medicine at the University of Pennsylvania after completing a Bachelor’s degree in Biology at La Salle University.